Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Mosonmagyaróvár – page 35

479 clinical trials in Mosonmagyaróvár, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mosonmagyaróvár at a glance
479
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

479 trials in Mosonmagyaróvár

Open in trial search

Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

C3 glomerulopathy

Not recruiting

Study on the Effectiveness and Safety of Iptacopan for Patients with Complement 3 Glomerulopathy

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on Ofatumumab for Patients with Relapsing Multiple Sclerosis Transitioning from Fumarate-Based Therapies or Fingolimod

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma+13

Not recruiting

Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Not recruiting

Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Children with Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

Breast cancer

Not recruiting

Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Mosonmagyaróvár

What the registry says about research in the country

01 Respiratory Medicine

Multiple innovative trials focusing on moderate to severe asthma management, testing new therapeutic approaches including lunsekimig, dupilumab, and amlitelimab. Research aims to prevent lung function decline and reduce exacerbations.

  • Asthma Exacerbation Prevention
  • Lung Function Preservation
  • Novel Treatment Evaluation

Studies particularly emphasize long-term safety and efficacy in patients with eosinophilic phenotype.

02 Pulmonary Disease Management

Clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD), evaluating new treatments like itepekimab and investigating improved delivery systems for existing medications.

  • COPD Exacerbation Reduction
  • Long-term Treatment Safety
  • Inhaler Technology Innovation

Emphasis on moderate to severe COPD patients and former smokers.

03 Cardiovascular Research

Comprehensive studies in heart failure and atrial fibrillation, testing breakthrough treatments including ponsegromab, milvexian, and vericiguat for improved patient outcomes.

  • Stroke Prevention
  • Heart Failure Management
  • Cardiovascular Event Prevention

Focus on reducing major adverse cardiovascular events and improving quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.